The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) has surged by 1.16 when compared to previous closing price of 1.72, but the company has seen a 10.13% gain in its stock price over the last five trading sessions. zacks.com reported 2025-04-09 that Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in Inovio Pharmaceuticals Inc (NASDAQ: INO) Right Now?
The 36-month beta value for INO is at 1.34. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for INO is 36.42M, and currently, shorts hold a 17.57% of that float. The average trading volume for INO on April 18, 2025 was 743.72K shares.
INO’s Market Performance
INO’s stock has seen a 10.13% increase for the week, with a -11.22% drop in the past month and a -8.90% fall in the past quarter. The volatility ratio for the week is 5.68%, and the volatility levels for the past 30 days are at 7.60% for Inovio Pharmaceuticals Inc The simple moving average for the past 20 days is 3.57% for INO’s stock, with a -63.14% simple moving average for the past 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with Stephens repeating the rating for INO by listing it as a “Overweight.” The predicted price for INO in the upcoming period, according to Stephens is $20 based on the research report published on May 14, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see INO reach a price target of $4. The rating they have provided for INO stocks is “Outperform” according to the report published on January 25th, 2024.
INO Trading at -7.69% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.05% of loss for the given period.
Volatility was left at 7.60%, however, over the last 30 days, the volatility rate increased by 5.68%, as shares sank -10.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.71% lower at present.
During the last 5 trading sessions, INO rose by +10.13%, which changed the moving average for the period of 200-days by -79.79% in comparison to the 20-day moving average, which settled at $1.6800. In addition, Inovio Pharmaceuticals Inc saw -4.92% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -516.17 for the present operating margin
- -6.29 for the gross margin
The net margin for Inovio Pharmaceuticals Inc stands at -115944.3. The total capital return value is set at -1.44. Equity return is now at value -115.42, with -74.52 for asset returns.
Based on Inovio Pharmaceuticals Inc (INO), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -7115.97. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -632.05.
Currently, EBITDA for the company is -103.95 million with net debt to EBITDA at 0.52. When we switch over and look at the enterprise to sales, we see a ratio of 45.3. The receivables turnover for the company is 0.18for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.77.
Conclusion
In conclusion, Inovio Pharmaceuticals Inc (INO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
